COMPANY INFO
Neuralink Corp. is an American neurotechnology company founded on June 21, 2016, by Elon Musk and a team of eight scientists and engineers. The company, headquartered in Fremont, California, has around 300 employees as of 2022 and focuses on developing implantable brain-computer interfaces to treat neurological disorders and enhance human capabilities. Their website is neuralink.com and they operate in the neurotechnology industry.
Neuralink Corp. is an American neurotechnology company founded in 2016 by Elon Musk, Max Hodak, Benjamin Rapoport, Dongjin Seo, Paul Merolla, Philip Sabes, Tim Gardner, Tim Hanson, and Vanessa Tolosa. Headquartered in Fremont, California, Neuralink specializes in developing implantable brain-computer interfaces (BCIs) aimed at treating neurological disorders and unlocking new human capabilities. With approximately 300 employees as of 2022, the company operates at the intersection of neuroscience and advanced engineering, striving to transform how people interact with technology and medical treatments. Neuralink’s innovations position it as a leader in the neurotechnology industry.
Neuralink Corp. funding history showcases a robust growth trajectory, with the company having raised approximately $1.29 billion across seven funding rounds. The company's funding strategy is characterized by substantial late-stage investments, with funding rounds supporting rapid product development, clinical trials, and scaling of manufacturing for its brain-machine interface devices. Neuralink funding rounds have attracted major interest from prominent venture capitalists and strategic investors, highlighting investor confidence in the firm’s ambitious technology roadmap. Notable milestones include the most recent $650 million Series E raise, positioning Neuralink to expand patient access to BCIs and to advance its clinical programs. Throughout its funding evolution, Neuralink investors have played pivotal roles in propelling the company toward the commercialization of breakthrough neurotechnology solutions.
This latest round was aimed at bringing Neuralink’s technology to more people, particularly those with severe paralysis, restoring independence for people with profound medical needs, and pushing the boundaries of brain interface innovation. The funds will support ongoing and future clinical trials and accelerate device deployment.
This round focused on accelerating the advancement of Brain-Computer Interface (BCI) technology, supporting upcoming clinical trials, and expanding Neuralink’s research and engineering teams.
Raised to further advance BCI technology and fund upcoming clinical trials, reinforcing Neuralink's commitment to pioneering neurotechnology research and device development.
The funds from this round were used to scale up company operations and prepare for large-scale clinical trials, with participation from several high-profile investors and technology visionaries.
This round funded deeper research and development efforts, focusing on the evolution of Neuralink’s brain-machine interface systems.
Series A supported product development for Neuralink’s first-generation brain-machine interface technology, cementing its early leadership in neurotechnology R&D.
Seed funding was used to launch the company and initiate its pioneering research into brain-computer interfaces.
Founders Fund is a top Silicon Valley venture capital firm that has repeatedly backed Neuralink with major investments in multiple rounds. Their continued involvement underscores strong confidence in Neuralink’s technology and long-term vision.
Vy Capital is a global technology investment company. Their participation in Neuralink’s Series C and subsequent rounds demonstrates their commitment to breakthrough neurotechnology and transformative ventures.
Google Ventures (now GV) joined Neuralink’s Series C, providing strategic insights and resources to help scale the company’s clinical and engineering operations.
DFJ Growth is a prominent venture capital investor in high-growth technology companies. They co-led Neuralink’s recent Series E and have actively supported the company’s latest innovation phases.
Valor Equity Partners is an operationally focused private equity and venture capital firm, supporting Neuralink’s capital-intensive phases and driving manufacturing scale-up.
Craft Ventures contributed to Neuralink funding in Series C, supporting its efforts to commercialize brain-machine interface technologies.
Gigafund is a long-term capital partner to transformative technology companies, backing Neuralink with investments that support research and clinical deployment.
Sam Altman, noted investor and entrepreneur, participated in Neuralink’s Series C. His involvement brings considerable technology expertise and influential sector relationships to Neuralink’s investor group.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Neuralink Corp. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.